EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China

Chen Liao, Li Bai iD, Tingting He, Qingle Liang iD, Defeng Hu, Shipeng Lei, Yong He iD, Yubo Wang iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Chen Liao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Chongqing University Jiangjin Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Uncommon EGFR mutations are a kind of heterogeneous group of mutations with various responses to EGFR‐TKIs and are often excluded from most prospective clinical trials. In this real‐world retrospective study, we retrospectively compared the efficacy and safety of chemotherapy or various generations of EGFR‐TKIs as first‐line therapy in NSCLC Chinese patients harboring non‐ex 20 ins uncommon EGFR mutations.

Methods

We enrolled 139 NSCLC patients with non‐ex 20 ins uncommon EGFR mutations in this study retrospectively. Patients' clinical characteristics and the efficacy and safety of different first‐line therapies were analyzed and compared.

Results

Our data reviewed that for first‐line therapy, NSCLC patients harboring non‐ex 20 ins uncommon EGFR mutations benefited more from EGFR‐TKIs compared with chemotherapy. Afatinib performed with great efficacy for the majority of non‐ex 20 ins uncommon EGFR mutations ( N = 43, ORR = 41.86%, mPFS = 13.5 months, mOS = 20.8 months), especially in L861Q mutation (mPFS = 18.4 months). Osimertinib also demonstrated efficacy in patients harboring non‐ex 20 ins uncommon EGFR mutations ( N = 36, ORR = 27.78%, mPFS = 10.0 months, mOS = 21.0 months), especially in those without L861Q and G719X mutations (mPFS = 12.1 months). When treated with afatinib, patients harboring non‐ex 20 ins uncommon EGFR mutations should pay attention to the management of safety, especially for gastrointestinal‐related AE and rash, while osimertinib was safer.

Conclusion

Taking into account both efficacy and safety, afatinib and osimertinib are better choices than chemotherapy and first‐generation EGFR‐TKIs for NSCLC patients with non‐ex 20 ins uncommon EGFR mutations. L861Q showed a trend toward a better response to afatinib, while in those without L861Q and G719X mutations, osimertinib might be a better choice. Safety also should be a concern when choosing EGFR‐TKI for treatment, patients should pay attention to the management of safety when using afatinib while osimertinib is safer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationProtein Kinase InhibitorsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedChinaAdultAfatinibAntineoplastic Combined Chemotherapy ProtocolsAniline CompoundsTreatment OutcomeAcrylamidesIndolesPyrimidines

Stichwörter der Autor:innen

EGFR‐TKINSCLCefficacysafetyuncommon EGFR mutation

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAfatinibAniline CompoundsAcrylamidesosimertinibIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.
  • Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army Medical University, Chongqing, China.
  • Department of Respiratory and Critical Care Medicine, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Clinical Laboratory Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.

ORCID-Profile: Li Bai, Qingle Liang, Yong He, Yubo Wang

Zitieren

APA

Liao, C., Bai, L., He, T., Liang, Q., Hu, D., Lei, S., He, Y., & Wang, Y. (2025). Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China. Cancer Medicine. https://doi.org/10.1002/cam4.70542

Vancouver

Liao C, Bai L, He T, Liang Q, Hu D, Lei S, et al. Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China. Cancer Medicine. 2025. doi:10.1002/cam4.70542

BibTeX
@article{Liao2025,
  author = {Liao, Chen and Bai, Li and He, Tingting and Liang, Qingle and Hu, Defeng and Lei, Shipeng and He, Yong and Wang, Yubo},
  title = {Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70542}
}
Kostenlos starten →